

William U. Parfet Joins inviCRO LLC's Board of Directors

William U. Parfet, Chairman, CEO, and President of MPI Research, lends his breadth of global expertise in preclinical drug and device development to support inviCRO's rapidly growing imaging services and software business

BOSTON, MA (September 30, 2014) – [inviCRO](#), a leading provider of imaging service solutions and analysis software for drug discovery and development, proudly announces the appointment of William U. Parfet, Chairman, CEO, and President of [MPI Research](#), to its Board of Directors. Mr. Parfet, Board shareholder, has extensive experience in the development and growth of leading Fortune 500 companies in the pharmaceutical, medical device and research industries.

“Bill’s insights into the global research and pharmaceutical industries, and his expertise in working to grow Fortune 500 organizations as a CEO and as a board member, will be invaluable to inviCRO as we continue to expand our research imaging services and software businesses,” said Jack Hoppin, Co-founder and Managing Director of inviCRO. “In addition, Bill is focused on trying to facilitate a new paradigm in cost-effective drug discovery and development that leverages bioinformatics to improve insights and efficiencies across all steps of the development process. This vision fits perfectly with the synergistic capabilities of inviCRO through the services and software-based solutions that we provide to our clients and to those of MPI Research”.

Parfet founded MPI Research in 1995, and formerly served as CEO and President of Richard-Allan Medical, a worldwide manufacturer of surgical products, in Richland, Michigan. Additionally, he served as the President, Executive Vice President, and Vice Chairman of the Board of The Upjohn Company (now recognized as Pfizer). Parfet serves on various other boards, including [Monsanto Company](#), [Stryker Corporation](#), Taubman Centers Inc., and Lake Forest College. He is also a member of the Taubman Medical Research (University of Michigan) Advisory Board.

Parfet’s recent involvement with inviCRO mirrors the new relationship between MPI Research and inviCRO as the two organizations, along with [3D Imaging](#), recently established the [Translational Imaging Center](#), the world’s first imaging and radiopharmaceutical production and services facility, in Mattawan, Michigan. The center, led by scientists from the three partner organizations, offers the most comprehensive array of imaging solutions. As the only of its kind, the center provides drug developers with magnetic resonance and translational nuclear imaging solutions (PET and SPECT) for both small and large molecules and from mouse models through to the clinic.



“I’m pleased to work with the very talented team at inviCRO as they further grow their business and expertise in imaging-based bioinformatics,” Parfet said. “In addition, the partnership between inviCRO, MPI Research, and 3D Imaging is working to revolutionize drug development and to accelerate the development of pharmaceuticals for use in disease treatment for humans,” he added. This recent collaboration will build upon the existing relationship between inviCRO and MPI Research, who together have already run and executed over 150 studies and whose union represents a leveraging of best-in-class union.

About inviCRO:

[inviCRO](#) is an imaging informatics company offering full-service tissue-to-human imaging, analysis and data management services powered by their industry-leading software platforms. In addition to their multi-modality imaging facility in Boston’s Innovation District, inviCRO’s services are delivered through a network of validated partners highlighted by the co-managed cyclotron facility at the [Translational Imaging Center](#) (inviCRO, MPI Research, 3DI). inviCRO’s image processing suite ([VivoQuant™](#)) and data management platform ([iPACS®](#)) are used by a majority of the top 25 pharmaceutical companies. The interdisciplinary team of inviCRO scientists have managed and/or processed 500+ imaging trials across a broad spectrum of therapeutic areas.

For more information, please contact:

Kat Ramey,
inviCRO, LLC
T. +1.617-904-2117
E. kramey@invicro.com
www.invicro.com